)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Roivant Sciences
Roivant Sciences (ROIV) investor relations material
Roivant Sciences Study result summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Study result summary21 Oct, 2026
Trial design
CLARITY-1 and CLARITY-2 were identical Phase 3 trials enrolling 371 adults with active, non-anterior NIU; participants received brepocitinib 45 mg once daily or placebo for 48 weeks.
The primary endpoint was time to treatment failure from Week 6 to Week 48; oral corticosteroids started at 60 mg, then tapered to zero by Week 8.
Primary efficacy
Both trials met the primary endpoint; median time to treatment failure exceeded 48 weeks with brepocitinib versus 13 weeks in CLARITY-1 and 12 weeks in CLARITY-2 (HR 0.27 and 0.22; p<0.0001 in both).
Pooled Week 48 treatment failure was 33.5% with brepocitinib versus 78.2% with placebo; among prior-TNFi patients, rates were 38.1% versus 77.5%.
Secondary outcomes
Pooled Week 48 steroid-free quiescence was 62% with brepocitinib versus 20% with placebo; results were consistent across subgroups.
Pooled macular edema resolution was 42% with brepocitinib versus 4.8% with placebo; FA response and VFQ-25 response also improved, and all key secondary endpoints were statistically significant in both trials.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Roivant Sciences
- Strong clinical progress and commercial focus drive expansion in autoimmune and orphan indications.ROIV
Bank of America Global Healthcare Conference - FDA approval, best-in-class PH-ILD data, and robust pipeline drive strong outlook.ROIVCitigroup’s Biopharma Back to School Summit 2026
- Mosliciguat's breakthrough data and brepocitinib's promising DM launch drive major pipeline momentum.ROIV12th Annual Cantor Fitzgerald Global Healthcare Conference
- PHocus trial data in PH-ILD and LISRAYA's launch highlight major advances and pipeline momentum.ROIVWells Fargo 21st Annual Healthcare Conference
- Mosliciguat delivered record PVR reduction, functional gains, and strong safety in PH-ILD.ROIVStudy result
- FDA approved LISRAYA as the first targeted oral therapy for dermatomyositis, launching immediately.ROIVFDA announcement
- $950M Moderna payment, $3.9B cash, and key product launch set for September 2026.ROIVQ1 2027
- Proxy covers director elections, auditor ratification, say-on-pay, and highlights governance and ESG.ROIVProxy filing
- Key votes include director elections, auditor ratification, and executive pay approval.ROIVProxy filing
Next Roivant Sciences earnings date
Q2 20279 Nov, 2026
Roivant Sciences
Next Roivant Sciences earnings date
Q2 20279 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage